PATENT CLAIM ANALYSIS

Application Number: 15934334
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "133100"]

Abstract:
Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

Claim (Index 58):
The method of  claim 57  which comprises one or more of the following;\n (i) the immune response is a Th1 immune response; \n (ii) the CD40 agonist is a CD40 agonistic antibody or a soluble CD40L fusion protein or soluble CD40 fragment or a conjugate thereof; \n (iii) the CD40 agonist is a chimeric, human or humanized antibody that specifically binds human CD40; \n (iv) the CD27 agonist is an anti-CD27 agonistic antibody or a soluble CD70 fusion protein or a soluble fragment or soluble conjugate thereof; \n (v) the method further includes the administration of an antigen selected from a tumor antigen, bacterial antigen, viral antigen, parasite antigen, allergen, and autoantigen; \n (vi) the agonistic anti-CD27 antibody is a chimeric, human or humanized antibody which is intact or modified; \n (vii) the CD27 agonist or the other agonist is attached to an effector moiety; \n (viii) the CD27 agonist or the other agonist is attached to an effector moiety selected from a toxin, drug and radionuclide; \n (ix) the CD27 agonist and the CD40 agonist are administered together or separately; \n (x) the CD27 agonist and the CD40 agonist are administered together and are contained in the same composition; \n (xi) either or both the CD27 agonist and the CD40 agonist comprise agonistic antibodies; \n (xii) the CD40 agonist is a soluble CD40L or soluble CD40 fusion protein; \n (xiii) the CD40 agonist and the CD27 agonist are administered separately from one another and administration may be effected in either order; optionally within one day of each other, within 8 hours of each other, or within 1-4 hours of each other; \n (xiv) the method further comprises the administration of a 4-1BB or 4-1BBL agonist, optionally an antibody; \n (xv) the method potentiates antigen-specific CD8 +  T cell immunity; \n (xvi) the method is used to treat human cancer, optionally a CD40 expressing cancer; \n (xvii) the method is used to treat a solid tumor; \n (xviii) the method is used to treat a cancer selected from the group consisting of: breast, liver, ovarian, colorectal, lung, stomach, kidney, melanoma, ovarian and lymphoma; \n (xix) the method is used to treat non-Hodgkin's lymphoma; \n (xx) the CD40 agonist is a chimeric, human or humanized anti-human CD40 antibody; \n (xxi) the method is used to treat renal cancer; \n (xxii) the method further includes administration of at least one chemotherapeutic; \n (xxiii) the method further includes administration of at least one cytokine, optionally an interferon, interleukin, tumor necrosis factor or colony stimulating factor; or (xxiv) the method is used to treat a subject with an autoimmune disease, inflammatory condition, infectious or allergic condition.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 90.0
- Lexical Diversity: 1.64835
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13905436', '12446322', '14974793', '11743978', '13165154']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.85164380530429
- 35 USC 102 Novelty (BERT): 0.6384142381241191
- Combined Prediction Score: 0.8303208485862729
- Mean Citation Score: 598.1939679999998
- Max Citation Score: 691.5565
- Similarity Product: 558.2510449974241

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test